Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Safety and Efficacy of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Participants With Chronic Hepatitis B (CHB) and Who Are Currently Not on Treatment

ClinicalTrials.gov ID: NCT02174276

Public ClinicalTrials.gov record NCT02174276. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects With Chronic Hepatitis B and Who Are Currently Not on Treatment

Study identification

NCT ID
NCT02174276
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Gilead Sciences
Industry
Enrollment
195 participants

Conditions and interventions

Interventions

  • Tenofovir disoproxil fumarate Drug
  • GS-4774 Biological

Drug · Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 23, 2014
Primary completion
Feb 16, 2016
Completion
May 29, 2018
Last update posted
Jun 3, 2019

2014 – 2018

United States locations

U.S. sites
12
U.S. states
7
U.S. cities
12
Facility City State ZIP Site status
Stanford University Medical Center Palo Alto California
Kaiser Permanente Sacramento California
Research and Education, Inc. San Diego California
Kaiser Permanente San Francisco San Francisco California
Silicon Valley Research Institute San Jose California
The Queen's Medical Center Honolulu Hawaii
Digestive Disease Associates, PA Baltimore Maryland
Tufts Medical Center Boston Massachusetts
Icahn School of Medicine at Mount Sinai New York New York
Xiaoli Ma, PC Philadelphia Pennsylvania
Virginia Commonwealth University Richmond Virginia
Kaiser Permanente Springfield Virginia

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02174276, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 3, 2019 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02174276 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →